Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Subscribe To Our Newsletter & Stay Updated